Orrick Advises Catalyst Biosciences on Underwritten Public Offering


Congratulations to Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, on its underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public.

The gross proceeds to Catalyst Biosciences from this offering are expected to be approximately $50 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst Biosciences. Piper, Sandler & Co., is acting as sole lead active bookrunner and Raymond James & Associates, Inc. is acting as a bookrunner. The offering is expected to close on or about January 29, 2021, subject to customary closing conditions.

The Orrick team advising Catalyst Biosciences includes Stephen Thau, Niki Fang, Vinella Sido, Kelly Mink and Nanette Agustines.